Pharmaceutical regulatory environment [electronic resource] : challenges and opportunities in the Gulf Region / Reem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.
2015
RS67.M628
Linked e-resources
Linked Resource
Online Access
Concurrent users
Unlimited
Authorized users
Authorized users
Document Delivery Supplied
Can lend chapters, not whole ebooks
Details
Title
Pharmaceutical regulatory environment [electronic resource] : challenges and opportunities in the Gulf Region / Reem K. Al-Essa, Mohammed Al-Rubaie, Stuart Walker, Sam Salek.
Author
Al-Essa, Reem K., author.
ISBN
9783319175904 electronic book
3319175904 electronic book
9783319175898
3319175904 electronic book
9783319175898
Published
Cham : Adis, 2015.
Language
English
Description
1 online resource
Item Number
10.1007/978-3-319-17590-4 doi
Call Number
RS67.M628
Dewey Decimal Classification
615.1093
Summary
The Middle East represents the next growth market for the global biopharmaceutical industry but to date there has been limited information about the regulatory review processes employed in these countries. A thorough examination of the strategies currently being implemented by the Gulf States is considered critical to the future regulatory environment in this region. This book compares national and centralised procedure practices and key performance metrics, including current approval times, review practices and pharmacovigilance standards, in the seven Gulf States. Opportunities for an improved regulatory system are identified, which, if fully implemented, could have a significant impact on patients? access to new medicines. Pharmaceutical Regulatory Environment: Challenges & Opportunities in the Gulf Region is a must read for those interested in pharmaceutical regulation in the Gulf region. Reem Al-Essa BPharm MSc PhD was the Drug Registration and Release Superintendent, Kuwait Ministry of Health, Drug and Food Control Department, for 12 years during which time she completed her MBA with distinction. She later undertook the EU2P MSc in Pharmacovigilance and Pharmacoepidemiology. Dr Al-Essa has published six journal articles and abstracts related to pharmaceutical regulation in the Gulf region. Mohammed Hamdan Al-Rubaie BPharm MSc PhD is the Director of Drug Control, Directorate General of Pharmaceutical affairs and Drug Control, Oman Ministry of Health.He is a member of the GCC Central Registration Committee, and actively involved in many other GCC committees and working groups for the drafting of the GCC pharmaceutical regulations and policies. Dr Al-Rubaie was instrumental in forming the Pharmaceutical society in Oman and chaired it from 2010-2011. Stuart Walker BSc, PhD, MFPM FRSC FIBiol, FRCPath, is the Founder of the Centre for Medicines Research International, the Centre for Innovation in Regulatory Science and Professor of Pharmaceutical Medicine, University of Wales, Cardiff. During his research career in academia & industry, he has supervised many PhD programmes in clinical development, regulatory policies, the benefit/risk assessment of medicines and health technology assessment, co-authored 280 research papers and edited 25 books. He is frequently involved in the organisation of international meetings on key issues that concern the regulatory review of medicines and has lectured extensively throughout Europe, the USA, the Asia-Pacific Region, Latin America and the Middle East. Sam Salek PhD RPh FFPM MRPSGB MCMS FESCP is Professor of Pharmacoepidemiology at the University of Hertfordshire, Hatfield, visiting Professor at the Estate of Hessen, Germany, and Director of the Institute for Medicines Development, Cardiff, UK. Professor Salek?s research focuses mainly on four areas: development and application of patient-reported outcome measures; drug safety evaluation and pharmacovigilance; pharmacoeconomics and economic evaluation of healthcare; and pharmaceutical regulation & medicines development in the mature and emerging markets. He has published 19 books and 600 journal articles and abstracts. Professor Salek is a member of five Editorial Boards and an active member of several societies.
Bibliography, etc. Note
Includes bibliographical references.
Access Note
Access limited to authorized users.
Source of Description
Online resource; title from PDF title page (viewed May 13, 2015)
Available in Other Form
Print version: 9783319175898
Linked Resources
Online Access
Record Appears in
Online Resources > Ebooks
All Resources
All Resources
Table of Contents
1. Overview of Medicines Regulatory Systems in the Gulf Region
2. The Regulatory Review Process in the Gulf Region
3. Regulatory Review Times in the Gulf Region
4. Quality Measures in the Gulf Regulatory Practices
5. The Current Status of the Common Technical Document
6. The Current Status of Drug Safety and Pharmacovigilance
7. The Centralized Regulatory Review in the Gulf Region
8. The Gulf States Assessment and Experience With the Centralised Procedure
9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure
10. Proposal For an Improved Centralized Regulatory System
11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions
12. The Regulatory Dilemma in the Gulf Region: The Way Forward.
2. The Regulatory Review Process in the Gulf Region
3. Regulatory Review Times in the Gulf Region
4. Quality Measures in the Gulf Regulatory Practices
5. The Current Status of the Common Technical Document
6. The Current Status of Drug Safety and Pharmacovigilance
7. The Centralized Regulatory Review in the Gulf Region
8. The Gulf States Assessment and Experience With the Centralised Procedure
9. The Pharmaceutical Companies Assessment and Experience With the Centralised Procedure
10. Proposal For an Improved Centralized Regulatory System
11. The Strategic Planning Process of the GCC Regulatory Authorities: Barriers And Solutions
12. The Regulatory Dilemma in the Gulf Region: The Way Forward.